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1. Introduction 
Circulating microemboli in the arterial system were detected using ultrasound as early as 
1969 (Spencer, Lawrence et al. 1969) (Fig 1). Microemboli to brain can be detected with high 
sensitivity using trancranial Doppler by insonating the middle cerebral arteries.  
 
 
Fig. 1. Microemboli from middle cerebral artery detected by TCD. 
The detection is made possible because of the acoustic impedance between microemboli and 
blood, which increases the ultrasound intensity. Microemboli are transient (<100ms), high 
intensity (> 3dB) and unidirectional signal which are accompanied by a characteristic click 
or chirp sound (Ringelstein, Droste et al. 1998). The origin of microemboli are usually from 
an atheromatous plaque in the carotid artery or the aorta, from the heart chambers in 
patients with atrial fibrillation, or from prosthetic heart valves.  
2. Characteristics of microemboli 
The detected signals are either of gaseous or solid embolic material (Russell, Madden et al. 
1991). Solid microemboli consist of platelet aggregates, thrombus or whole blood (Markus 
and Brown 1993). Platelet aggregates are usually ruptured off an atheromatous plaque 
because of the shear stress on vessel wall (Kessler 1992). Postmortem studies have shown 
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that solid microemboli contain lipids in addition to small birefrigent particles  
(Brown, Moody et al. 1996). The gaseous microemboli usually originates from a prosthetic 
heart valve. It is created by mechanically induced cavitations. A reliable differentiation 
between gaseous and solid microemboli is not possible with single frequency probe  
that are being currently used in most centers (Dittrich, Ritter et al. 2002). Newly  
available dual frequency probes can reliably differentiate between solid and gaseous 
microemboli. However, such differentiation is not of much significance in most patient 
subgroups.  
3. Impact of microemboli on brain 
Solid microemboli are much bigger than gaseous microemboli, having an approximate 
diameter of 100 µm and 4µm respectively. The larger size of solid microemboli compared to 
capillaries (diameter 7-10 µm) can cause blockade of microcirculation. Solid microemboli, 
which predominantly arises from atheromatous plaque, can cause injury to the brain, which 
may manifest as cognitive impairement. Histological studies have shown that such 
microemboli leads to loss of enzymatic activities of endothelial cells leading to degeneration 
of capillaries (Brown, Moody et al. 1996). These microemboli usually disappear from brain 
within two weeks, but can persist there for up to 6 months. In contrast gaseous microemboli, 
predominantly seen in patients with prosthetic valve, have no deleterious effect on brain 
(Kaps, Hansen et al. 1997). 
4. Prevalence 
Prevalence of microemboli varies in different patient sub-groups. An estimated 
prevalence of 1-5% is estimated in the general population based on small control  
groups from different studies(Daffertshofer, Ries et al. 1996) (Georgiadis, Lindner et al. 
1997). The prevalence is higher in high-risk patients who are vulnerable to 
thromboembolic events.   
4.1 Prevalence in acute ischemic stroke 
A large proportion of ischemic stroke is of embolic etiology. Therefore, assessing  
the prevalence of microemboli following ischemic stroke is of great interest. Very few 
studies have assessed the prevalence of microemboli in the acute phase of stroke because 
of the technical difficulties. The available studies in the acute phase of stroke  
(<24 hours) have shown the prevalence of microemboli to be between 19-49% (Sliwka, 
Lingnau et al. 1997; Delcker, Schnell et al. 2000; Iguchi, Kimura et al. 2008; Idicula, Naess 
et al. 2010). However monitoring beyond the first 24 hours after stroke shows a lower 
prevalence ranging from 6 to 32% (Tong and Albers 1995; Del Sette, Angeli et al. 1997; 
Koennecke, Mast et al. 1998; Valton, Larrue et al. 1998; Kaposzta, Young et al. 1999; Lund, 
Rygh et al. 2000; Serena, Segura et al. 2000; Gucuyener, Uzuner et al. 2001; Poppert, 
Sadikovic et al. 2006). The prevalence of microemboli in the largest of those studies 
(n=653) was less than 6% (Poppert, Sadikovic et al. 2006). It seems like there is an inverse 
relationship between timing of monitoring and the prevalence of microemboli following 
acute ischemic stroke. Table 1 shows the prevalence of microemboli following ischemic 
stroke in various studies. 
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Table 1. The prevalence of microemboli in various studies performed before and after 24 
hours of stroke onset in various studies. 
4.2 Prevalence in atherosclerotic carotid artery disease 
The prevalence of microemboli is high in patients with large artery disease as in carotid 
artery stenosis. Table 2 shows a review of all studies in which prevalence of microemboli 
was assessed in symptomatic and asymptomatic carotid stenosis (Babikian, Hyde et al. 1994; 
Siebler, Kleinschmidt et al. 1994; Markus and Harrison 1995; Daffertshofer, Ries et al. 1996; 
Georgiadis, Lindner et al. 1997; Markus and MacKinnon 2005; Spence, Tamayo et al. 2005; 
Zuromskis, Wetterholm et al. 2008). 
 
Author n Symptomatic(%) Asymptomatic(%) 
Zuromskis 197 32 4.5 
Georgiadis 500 52 7 
Siebler 89 82  
Babikian 75 28  
Daffertshofer 280 9  
Markus 38 34 3.5 
Markus 230 48  
Spence 319  10 
Table 2. Shows the prevalence of microemboli in symptomatic and asymptomatic carotid 
artery disease. 
While the prevalence of microemboli in patients with carotid stenosis ranged from 20-90%, 
most of the studies showed a prevalence of more than 30% in symptomatic carotid stenosis 
(Markus and Harrison 1995). The large variation in the prevalence of microemboli in 
different studies may be attributed to differences in the timing of study, use of antiplatelet 
agents at the time of monitoring and the sample population itself. However the studies, 
which compared prevalence of microemboli in symptomatic and asymptomatic side, clearly 
shows a higher prevalence in the symptomatic side. A recent pooled analysis of 
microemboli in patients with symptomatic and asymptomatic carotid stenosis showed a 
prevalence of 42% and 8% respectively (Ritter, Dittrich et al. 2008).   
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4.3 Prevalence in intracranial stenosis 
The prevalence microemboli in intracranial stenosis is less well studied compared to carotid 
stenosis. A review of those studies is given in table 3.  
 
Author n Symptomatic Asymptomatic
Wong 60 15 0





Table 3. Shows the prevalence of microemboli in the symptomatic and asymptomatic 
intracranial stenosis in various studies. 
The available data shows that the prevalence of microemboli in intracranial stenosis to be 
between 7-33% (Nabavi, Georgiadis et al. 1996; Segura, Serena et al. 2001; Wong, Gao et al. 
2001; Droste, Junker et al. 2002; Wong, Gao et al. 2002; Gao, Wong et al. 2004). The 
prevalence of microemboli in the largest of those studies (n=114) was 22%. The prevalence 
of microemboli in asymptomatic stenosis were between 0-7% (Nabavi, Georgiadis et al. 
1996; Wong, Gao et al. 2001). A pooled analysis of patients with intracranial stenosis shows 
the prevalence of microemboli in the symptomatic and asymptomatic side to be 25% and 0% 
respectively (Ritter, Dittrich et al. 2008). Overall, the prevalence of microemboli in 
intracranial stenosis is lower compared to carotid artery stenosis. Lower prevalence of 
microemboli in intracranial stenosis may be because of the technical difficulty in performing 
microemboli monitoring in the presence of intracranial stenosis as well as the difference in 
plaque morphology.     
4.4 Prevalence in various cardiac diseases 
Microemboli from the heart originate either from the heart chambers itself or from 
prosthetic heart valves. Parallel to the known risk factors for cardioembolic stroke, 
microemboli are often observed in atrial fibrillation, prosthetic heart valves, patent foramen 
ovale, acute myocardial infarction and left ventricular dysfunction. The highest prevalence 
of microemboli is seen in patients with prosthetic heart valves, about 60% with mechanical 
prosthetic heart valves and about 10% with biological prosthetic heart valves (Eicke, Barth et 
al. 1996). In patients with atrial fibrillation, the prevalence of microemboli seems to be 
higher in symptomatic atrial fibrillation (29%) as opposed to asymptomatic atrial fibrillation 
(10%) (Kumral, Balkir et al. 2001).  Similarly, there is a higher prevalence of microemboli in 
valvular atrial fibrillation as opposed to non-valvular atrial fibrillation corresponding to a 
higher risk for thromboembolic events (Kumral, Balkir et al. 2001). Except for mechanical 
prosthetic heart valves, the overall prevalence of microemboli in various heart conditions 
seems to be lesser than in carotid artery disease.    
5. Application of microemboli monitoring 
5.1 Application of microemboli monitoring in acute stroke 
It is optimal to perform microemboli monitoring closer to the onset of symptoms because of 
the inverse relationship between timing of monitoring and the prevalence of microemboli 
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(Forteza, Babikian et al. 1996). The technical difficulty and the need for manpower make it 
difficult to perform monitoring within the first 24 hours after stroke onset. However, it may 
still be adequate to perform monitoring after the first 24 hours. Identification of microemboli 
will help us understand the etiology, predict outcome and assess the effectiveness of 
secondary prophylaxis.  
5.1.1 Assessing the etiology of stroke 
TOAST is one of the commonly used classifications to define stroke etiology. However, this 
classification fails to clearly define etiology in more than one third of the patients 
(Kolominsky-Rabas, Weber et al. 2001). More tools are needed to determine stroke etiology 
reliably. Microemboli are generally found in patients with embolic etiologies, both of  
arterial  and of cardiac origin. A review of studies conducted in ischemic stroke patients 
shows that microemboli are mostly present when an embolic source is present (Del Sette, 
Angeli et al. 1997; Sliwka, Lingnau et al. 1997; Koennecke, Mast et al. 1998; Kaposzta, Young 
et al. 1999; Lund, Rygh et al. 2000; Serena, Segura et al. 2000; Poppert, Sadikovic et al. 2006; 
Iguchi, Kimura et al. 2008; Idicula, Naess et al. 2010). Some studies have, however, shown 
the presence of microemboli in lacunar stroke, even though less frequent than in other 
etiologies (Koennecke, Mast et al. 1998; Lund, Rygh et al. 2000; Iguchi, Kimura et al. 2008). 
Microemboli were absent in all lacunar stroke patients in most other studies including the 
largest of them (Poppert, Sadikovic et al. 2006). Even though the specificity of microemboli 
in determining an embolic etiology is not fully known, the presence of microemboli strongly 
suggests the possibility of an embolic source. Further differentiation between large-artery 
and cardioembolic stroke can also be made based on characteristics of microemboli. Bilateral 
microemboli may suggest microemboli from heart or arch of aorta (Kaposzta, Young et al. 
1999), whereas unilateral microemboli suggest carotid artery stenosis or intracranial artery 
stenosis. This can especially be relevant when two potential embolic sources are 
simultaneously present as in carotid stenosis along with atrial fibrillation. Specificity of 
bilateral microemboli in determining cardiac source of embolism can further be improved 
by recording both the proximal carotid arteries and both middle cerebral arteries 
simultaneously. 
5.1.2 Predicting outcome after stroke 
The value of microemboli in predicting outcome and future vascular events following an 
ischemic stroke is known only to a limited extent due to the lack of sufficient studies. A 
review of all studies involving 602 patients reveals an interesting finding. All except one 
study showed that microemboli is an independent predictor of future vascular events with 
an odds ratio of 4 or above (Valton, Larrue et al. 1998; Censori, Partziguian et al. 2000; Gao, 
Wong et al. 2004; Markus and MacKinnon 2005; Iguchi, Kimura et al. 2008; Idicula, Naess et 
al. 2010). It infers that microemboli monitoring may be of value in predicting recurrence 
following acute ischemic stroke.    
The functional outcome or disability after stroke is, however, less well predicted by the presence 
or absence of microemboli. Two studies in which data on functional outcome was available 
failed to observe any association between microemboli and functional outcome (Delcker, 
Schnell et al. 2000; Idicula, Naess et al. 2010). One of the studies showed a trend towards higher 
mortality among patients with microemboli, but the association was not significant after 
adjusting for confounding factors (Idicula, Naess et al. 2010). Thus, there is a paucity of 
evidence to suggest that microemboli predict poor functional outcome after ischemic stroke.  
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5.1.3 Assessing efficacy of secondary prophylaxis  
Many platelet inhibitors are approved for secondary prophylaxis after ischemic stroke. It is 
difficult to predict which of the approved agents would be a better alternative in an 
individual patient. Microembolic mostly consist of platelet aggregates. Therefore, their 
measurement may be used as a surrogate marker for evaluating anti-platelet effect (Wong 
2005). Glycoprotein IIb/IIIa receptor antagonist such as tirofiban infusion has shown to 
reduce the rate of microemboli and the effect was reversible with the cessation of infusion 
(Junghans and Siebler 2003). Administration of intravenous and oral acetylsalicyclic acid 
(ASA) has shown to reduce the frequency of microemboli rapidly (Goertler, Baeumer et al. 
1999; Goertler, Blaser et al. 2001). Several small studies have shown that dual antiplatelet 
therapy might lead to rapid decline in microembolic frequency (Esagunde, Wong et al. 
2006). The studies were not double blinded randomized studies. However, they showed that 
the frequency of microemboli was significantly reduced after administering antiplatelet 
agents. It indicates the potential of measuring microemboli as a surrogate marker of anti-
platelet effect. This is particularly important in patients with recent symptomatic carotid 
stenosis.  
In CARESS trial, a randomized double-blind study, patients with symptomatic carotid 
stenosis were randomized to either aspirin alone or aspirin and clopidogrel. Patients who 
received dual anti-platelet therapy with aspirin and clopidogrel had significantly lower 
microemboli compared to patients who received aspirin alone (Markus, Droste et al. 2005). 
Subsequently, fewer recurrent ischemic events were observed in patients who received dual 
antiplatelet therapy (Mackinnon, Aaslid et al. 2005). Dual antiplatelet therapy with aspirin 
and clopidogrel may be an optimal choice at least in a subgroup of high-risk stroke patients 
who can be identified with the help of microemboli monitoring. However, the long-term 
outcome or the optimal duration of dual antiplatelet therapy is not known yet. On the 
contrary, the effect of anticoagulation on microemboli is highly uncertain. Except for some 
anecdotal reports, there is no evidence that anticoagulation would abort microemboli 
(Poppert, Sadikovic et al. 2006).   
5.2 Application of microemboli monitoring in carotid artery and intracranial artery 
stenosis 
Microemboli from an unstable carotid plaque often represent inflammation within the 
plaque (Jander, Sitzer et al. 1998). Studies with FDG-PET in patients with carotid plaque 
have shown that patients with microemboli are more likely to have inflammation within the 
plaque (Moustafa, Izquierdo-Garcia et al. 2010). Plaque specimens in patients undergoing 
endarterectomy have shown that presence of microemboli is strongly associated with plaque 
fissuring and luminal thrombosis (Sitzer, Siebler et al. 1995). In patients with symptomatic 
carotid stenosis, microemboli is an indicator of plaque instability (Siebler, Kleinschmidt et 
al. 1994). Carotid endarterectomy results in drastic reduction or disappearance of 
microemboli (Orlandi, Parenti et al. 1997).  Similarly, patients with asymptomatic carotid 
stenosis microemboli have proven to be a known marker of future vascular events as shown 
in several studies (Siebler, Nachtmann et al. 1995; Molloy and Markus 1999). Thus, the 
presence of microemboli might help choose the right therapeutic option including 
endarterectomy especially in patients with asymptomatic stenosis. Microemboli monitoring 
is also important in patients with intracranial artery disease as well. Even though there are 
technical difficulties in performing microemboli monitoring in the presence of intracranial 
stenosis, the presence of microemboli provides valuable information to choose appropriate 
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management. The frequency of microemboli in the presence of intracranial artery stenosis 
has shown to be associated with the number of infarcts on imaging (Wong, Gao et al. 2002). 
In patients with frequent microemboli, dual antiplatelet agents has shown to reduce the 
frequency of microemboli from intracranial stenosis as in carotid artery stenosis (Sebastian, 
Derksen et al. 2011), arguing in favour of using it in those patients.  
5.3 Application of microemboli monitoring in heart diseases 
The clinical and prognostic significance of microemboli in patients with atrial fibrillation 
and prosthetic valves is unclear. Only few studies have shown that anticoagulation may 
reduce microembolic frequency in patients with atrial fibrillation (Tinkler, Cullinane et al. 
2002).  It is difficult to choose between anticoagulation versus anti-platelet agents based on 
the presence or absence of microemboli. However, the presence of microemboli may prompt 
the use either anticoagulation or anti-platelet agents in patients with atrial fibrillation 
regardless of any thromboembolic events.     
5.4 Application of microemboli monitoring in special situations 
5.4.1 Arterial dissection  
As in embolic stroke, microemboli are often seen in patients with dissection. More 
microemboli are present in patients who present with stroke symptoms as opposed to local 
symptoms (Ritter, Dittrich et al. 2008). Presence of microemboli seems to be a predictor of 
stroke recurrence (Molina, Alvarez-Sabin et al. 2000). Microemboli are seen both in 
dissection of carotid and vertebral arteries, and possibly predict thromboembolic events 
(Droste, Junker et al. 2001). Presence of microemboli may be a determining factor in 
choosing the right medication, favoring anticoagulation over antiplatelet agents (Engelter, 
Brandt et al. 2007).   
5.4.2 Monitoring during and after carotid endarterectomy 
Presence of microemboli during carotid endarterectomy is an indicator of new ischemic 
events (Ackerstaff, Moons et al. 2000) (Ackerstaff, Jansen et al. 1995). Presence of 
microemboli should alert the physician to change the surgical technique. Ongoing 
microemboli after endarterectomy indicates other sources of emboli, which prompt 
reassessment of the operated carotid as well as searching for other sources.   
6. Uncertainties and future directives 
Microembolic signals have been identified in a number of clinical neurovascular settings 
with a variety of embolic sources, but predominantly in patients with large vessel 
atherosclerosis. In these patients microembolic signals may be an independent predictor of 
future stroke or TIA, but the association between microembolic signals and long-term 
clinical outcome has not always been found (Lund, Rygh et al. 2000; Abbott, Chambers et al. 
2005). Research has mainly focused on quantity, i.e. presence or frequency of microemboli, 
but less on quality, i.e. size or constituents of microemboli due to technical limitations. After 
years of studies, the relevance of microemboli in the individual patient with acute stroke 
remains elusive and uncertainty prevails. There may be several reasons for this, of which the 
timing of assessment may be of great relevance. Studies have been performed within 24 
hours, 48 hours, 72 hours, or even 7 days. The implications of microemboli in the early hours 
after stroke may be different from those at later stages. The number of microemboli seems to 
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be inversely associated with the time from stroke onset. Early microemboli may reflect an 
ongoing acute vascular process, which might be satisfactorily controlled with adequate 
antithrombotic and statin treatment. Late microemboli persisting in spite of adequate 
treatment may reflect a true malignant vascular process with a high risk of future stroke. 
And in between, there is a transition time zone with microemboli of possibly varying long-
term clinical relevance. Embolization is, however, not a continuous or a random process. 
Embolization occurs with temporal clustering and may occur outside the microemboli 
monitoring time window. Strength of TCD monitoring is it’s time resolution. It is 
conceivable that repeated microemboli monitoring over time will yield more information 
than what a short glimpse at one single time-point does. The temporal variability of 
embolization underlines the need for repeated long-lasting microemboli monitoring to 
improve estimation of true embolic load and pattern of embolization (Mackinnon, Aaslid et 
al. 2005).  
The size of an embolus is of obvious relevance. Although embolic signals become more 
intense with increasing thrombus size, there is currently no method for estimating size 
(Martin, Chung et al. 2009). Low-intensity signals are routinely rejected in standard 
monitoring set-up, but there may be many real microemboli among these low-intensity 
microemboli signals, and the presence of low-intensity microemboli signals significantly 
increases the chance of finding high-intensity microemboli signals (Telman, Sprecher et al. 
2011). Therefore, low-intensity microemboli signals need increased attention as a possible 
marker of clinically significant embolization.  Quality of microemboli may be further 
analyzed using transcranial power M-mode Doppler and an energy signature. This 
approach may define a subgroup of patients with malignant microemboli, who have larger 
baseline infarcts, and worse clinical outcome (Choi, Saqqur et al. 2010). In general, careful 
assessment of diffusion-weighted MRI may give indirect evidence of the size of microemboli 
(Droste, Knapp et al. 2007).  
Microemboli are markers of disease activity, not the disease itself. Microemboli have been 
associated with carotid plaque inflammation (Moustafa, Izquierdo-Garcia et al. 2010), 
coagulopathies (Seok, Kim et al. 2010) and platelet activation markers (Ritter, Jurk et al. 
2009). Adding information on basic disease mechanisms may improve our understanding of 
the complex pathophysiology of acute embolic stroke as defined by MES monitoring. 
7. Conclusion 
The assessment of microemboli in acute stroke needs to move from quantity to quality, 
taking into account the natural variability in embolization rates and the temporal clustering 
of embolization. There is need to establish optimal monitoring protocols with extensive time 
windows. The emboli as such need to be understood within the complex framework of acute 
stroke, including vessel wall or cardiac pathology, inflammation and coagulation, as well as 
end-organ damage. Multimodal approach, including transcranial microemboli monitoring, 
is a prerequisite for future advances in embolic stroke. 
8. References 
Abbott, A. L., B. R. Chambers, et al. (2005). "Embolic signals and prediction of ipsilateral 
stroke or transient ischemic attack in asymptomatic carotid stenosis: a multicenter 
prospective cohort study." Stroke 36(6): 1128-33. 
www.intechopen.com
 
Microemboli Monitoring in Ischemic Stroke 
 
153 
Ackerstaff, R. G., C. Jansen, et al. (1995). "The significance of microemboli detection by 
means of transcranial Doppler ultrasonography monitoring in carotid 
endarterectomy." J Vasc Surg 21(6): 963-9. 
Ackerstaff, R. G., K. G. Moons, et al. (2000). "Association of intraoperative transcranial 
doppler monitoring variables with stroke from carotid endarterectomy." Stroke 
31(8): 1817-23. 
Babikian, V. L., C. Hyde, et al. (1994). "Clinical correlates of high-intensity transient signals 
detected on transcranial Doppler sonography in patients with cerebrovascular 
disease." Stroke 25(8): 1570-3. 
Brown, W. R., D. M. Moody, et al. (1996). "Histologic Studies of Brain Microemboli in 
Humans and Dogs After Cardiopulmonary Bypass." Echocardiography 13(5): 559-
566. 
Censori, B., T. Partziguian, et al. (2000). "Doppler microembolic signals predict ischemic 
recurrences in symptomatic carotid stenosis." Acta Neurol Scand 101(5): 327-31. 
Choi, Y., M. Saqqur, et al. (2010). "Relative energy index of microembolic signal can predict 
malignant microemboli." Stroke 41(4): 700-6. 
Daffertshofer, M., S. Ries, et al. (1996). "High-intensity transient signals in patients with 
cerebral ischemia." Stroke 27(10): 1844-9. 
Del Sette, M., S. Angeli, et al. (1997). "Microembolic signals with serial transcranial Doppler 
monitoring in acute focal ischemic deficit. A local phenomenon?" Stroke 28(7): 1311-
3. 
Delcker, A., A. Schnell, et al. (2000). "Microembolic signals and clinical outcome in patients 
with acute stroke--a prospective study." Eur Arch Psychiatry Clin Neurosci 250(1): 1-
5. 
Dittrich, R., M. A. Ritter, et al. (2002). "Microembolus detection by transcranial doppler 
sonography." Eur J Ultrasound 16(1-2): 21-30. 
Droste, D. W., K. Junker, et al. (2002). "Circulating microemboli in 33 patients with 
intracranial arterial stenosis." Cerebrovasc Dis 13(1): 26-30. 
Droste, D. W., K. Junker, et al. (2001). "Clinically silent circulating microemboli in 20 patients 
with carotid or vertebral artery dissection." Cerebrovasc Dis 12(3): 181-5. 
Droste, D. W., J. Knapp, et al. (2007). "Diffusion weighted MRI imaging and MES detection 
in the assessment of stroke origin." Neurol Res 29(5): 480-4. 
Eicke, B. M., V. Barth, et al. (1996). "Cardiac microembolism: prevalence and clinical 
outcome." J Neurol Sci 136(1-2): 143-7. 
Engelter, S. T., T. Brandt, et al. (2007). "Antiplatelets versus anticoagulation in cervical artery 
dissection." Stroke 38(9): 2605-11. 
Esagunde, R. U., K. S. Wong, et al. (2006). "Efficacy of dual antiplatelet therapy in 
cerebrovascular disease as demonstrated by a decline in microembolic signals. A 
report of eight cases." Cerebrovasc Dis 21(4): 242-6. 
Forteza, A. M., V. L. Babikian, et al. (1996). "Effect of time and cerebrovascular symptoms of 
the prevalence of microembolic signals in patients with cervical carotid stenosis." 
Stroke 27(4): 687-90. 
Gao, S., K. S. Wong, et al. (2004). "Microembolic signal predicts recurrent cerebral ischemic 




Acute Ischemic Stroke 
 
154 
Georgiadis, D., A. Lindner, et al. (1997). "Intracranial microembolic signals in 500 patients 
with potential cardiac or carotid embolic source and in normal controls." Stroke 
28(6): 1203-7. 
Goertler, M., M. Baeumer, et al. (1999). "Rapid decline of cerebral microemboli of arterial 
origin after intravenous acetylsalicylic acid." Stroke 30(1): 66-9. 
Goertler, M., T. Blaser, et al. (2001). "Acetylsalicylic acid and microembolic events detected 
by transcranial Doppler in symptomatic arterial stenoses." Cerebrovasc Dis 11(4): 
324-9. 
Gucuyener, D., N. Uzuner, et al. (2001). "Micro embolic signals in patients with cerebral 
ischaemic events." Neurol India 49(3): 225-30. 
Idicula, T. T., H. Naess, et al. (2010). "Microemboli-monitoring during the acute phase of 
ischemic stroke: is it worth the time?" BMC Neurol 10: 79. 
Iguchi, Y., K. Kimura, et al. (2008). "Microembolic signals at 48 hours after stroke onset 
contribute to new ischaemia within a week." J Neurol Neurosurg Psychiatry 79(3): 
253-9. 
Jander, S., M. Sitzer, et al. (1998). "Inflammation in high-grade carotid stenosis: a possible 
role for macrophages and T cells in plaque destabilization." Stroke 29(8): 1625-30. 
Junghans, U. and M. Siebler (2003). "Cerebral microembolism is blocked by tirofiban, a 
selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist." Circulation 
107(21): 2717-21. 
Kaposzta, Z., E. Young, et al. (1999). "Clinical application of asymptomatic embolic signal 
detection in acute stroke: a prospective study." Stroke 30(9): 1814-8. 
Kaps, M., J. Hansen, et al. (1997). "Clinically silent microemboli in patients with artificial 
prosthetic aortic valves are predominantly gaseous and not solid." Stroke 28(2): 322-
5. 
Kessler, C. M. (1992). "Intracerebral platelet accumulation as evidence for embolization of 
carotid origin." Clin Nucl Med 17(9): 728-9. 
Koennecke, H. C., H. Mast, et al. (1998). "Frequency and determinants of microembolic 
signals on transcranial Doppler in unselected patients with acute carotid territory 
ischemia. A prospective study." Cerebrovasc Dis 8(2): 107-12. 
Kolominsky-Rabas, P. L., M. Weber, et al. (2001). "Epidemiology of ischemic stroke subtypes 
according to TOAST criteria: incidence, recurrence, and long-term survival in 
ischemic stroke subtypes: a population-based study." Stroke 32(12): 2735-40. 
Kumral, E., K. Balkir, et al. (2001). "Microembolic signal detection in patients with 
symptomatic and asymptomatic lone atrial fibrillation." Cerebrovasc Dis 12(3): 192-6. 
Lund, C., J. Rygh, et al. (2000). "Cerebral microembolus detection in an unselected acute 
ischemic stroke population." Cerebrovasc Dis 10(5): 403-8. 
Mackinnon, A. D., R. Aaslid, et al. (2005). "Ambulatory transcranial Doppler cerebral 
embolic signal detection in symptomatic and asymptomatic carotid stenosis." Stroke 
36(8): 1726-30. 
Markus, H. S. and M. M. Brown (1993). "Differentiation between different pathological 
cerebral embolic materials using transcranial Doppler in an in vitro model." Stroke 
24(1): 1-5. 
Markus, H. S., D. W. Droste, et al. (2005). "Dual antiplatelet therapy with clopidogrel and 
aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal 
www.intechopen.com
 
Microemboli Monitoring in Ischemic Stroke 
 
155 
detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic 
Carotid Stenosis (CARESS) trial." Circulation 111(17): 2233-40. 
Markus, H. S. and M. J. Harrison (1995). "Microembolic signal detection using ultrasound." 
Stroke 26(9): 1517-9. 
Markus, H. S. and A. MacKinnon (2005). "Asymptomatic embolization detected by Doppler 
ultrasound predicts stroke risk in symptomatic carotid artery stenosis." Stroke 36(5): 
971-5. 
Martin, M. J., E. M. Chung, et al. (2009). "Thrombus size and Doppler embolic signal 
intensity." Cerebrovasc Dis 28(4): 397-405. 
Molina, C. A., J. Alvarez-Sabin, et al. (2000). "Cerebral microembolism in acute spontaneous 
internal carotid artery dissection." Neurology 55(11): 1738-40. 
Molloy, J. and H. S. Markus (1999). "Asymptomatic embolization predicts stroke and TIA 
risk in patients with carotid artery stenosis." Stroke 30(7): 1440-3. 
Moustafa, R. R., D. Izquierdo-Garcia, et al. (2010). "Carotid plaque inflammation is 
associated with cerebral microembolism in patients with recent transient ischemic 
attack or stroke: a pilot study." Circ Cardiovasc Imaging 3(5): 536-41. 
Nabavi, D. G., D. Georgiadis, et al. (1996). "Detection of microembolic signals in patients 
with middle cerebral artery stenosis by means of a bigate probe. A pilot study." 
Stroke 27(8): 1347-9. 
Orlandi, G., G. Parenti, et al. (1997). "Silent cerebral microembolism in asymptomatic and 
symptomatic carotid artery stenoses of low and high degree." Eur Neurol 38(1): 39-
43. 
Poppert, H., S. Sadikovic, et al. (2006). "Embolic signals in unselected stroke patients: 
prevalence and diagnostic benefit." Stroke 37(8): 2039-43. 
Ringelstein, E. B., D. W. Droste, et al. (1998). "Consensus on microembolus detection by 
TCD. International Consensus Group on Microembolus Detection." Stroke 29(3): 
725-9. 
Ritter, M. A., R. Dittrich, et al. (2008). "Prevalence and prognostic impact of microembolic 
signals in arterial sources of embolism. A systematic review of the literature." J 
Neurol 255(7): 953-61. 
Ritter, M. A., K. Jurk, et al. (2009). "Microembolic signals on transcranial Doppler ultrasound 
are correlated with platelet activation markers, but not with platelet-leukocyte 
associates: a study in patients with acute stroke and in patients with asymptomatic 
carotid stenosis." Neurol Res 31(1): 11-6. 
Russell, D., K. P. Madden, et al. (1991). "Detection of arterial emboli using Doppler 
ultrasound in rabbits." Stroke 22(2): 253-8. 
Sebastian, J., C. Derksen, et al. (2011). "The role of transcranial Doppler embolic monitoring 
in the management of intracranial arterial stenosis." J Neuroimaging 21(2): e166-8. 
Segura, T., J. Serena, et al. (2001). "Embolism in acute middle cerebral artery stenosis." 
Neurology 56(4): 497-501. 
Seok, J. M., S. G. Kim, et al. (2010). "Coagulopathy and embolic signal in cancer patients with 
ischemic stroke." Ann Neurol 68(2): 213-9. 
Serena, J., T. Segura, et al. (2000). "Microembolic signal monitoring in hemispheric acute 
ischaemic stroke: a prospective study." Cerebrovasc Dis 10(4): 278-82. 
Siebler, M., A. Kleinschmidt, et al. (1994). "Cerebral microembolism in symptomatic and 
asymptomatic high-grade internal carotid artery stenosis." Neurology 44(4): 615-8. 
www.intechopen.com
 
Acute Ischemic Stroke 
 
156 
Siebler, M., A. Nachtmann, et al. (1995). "Cerebral microembolism and the risk of ischemia 
in asymptomatic high-grade internal carotid artery stenosis." Stroke 26(11): 2184-6. 
Sitzer, M., M. Siebler, et al. (1995). "Cerebral microembolism in atherosclerotic carotid artery 
disease: facts and perspectives." Funct Neurol 10(6): 251-8. 
Sliwka, U., A. Lingnau, et al. (1997). "Prevalence and time course of microembolic signals in 
patients with acute stroke. A prospective study." Stroke 28(2): 358-63. 
Spence, J. D., A. Tamayo, et al. (2005). "Absence of microemboli on transcranial Doppler 
identifies low-risk patients with asymptomatic carotid stenosis." Stroke 36(11): 2373-
8. 
Spencer, M. P., G. H. Lawrence, et al. (1969). "The use of ultrasonics in the determination of 
arterial aeroembolism during open-heart surgery." Ann Thorac Surg 8(6): 489-97. 
Telman, G., E. Sprecher, et al. (2011). "Potential relevance of low-intensity microembolic 
signals by TCD monitoring." Neurol Sci 32(1): 107-11. 
Tinkler, K., M. Cullinane, et al. (2002). "Asymptomatic embolisation in non-valvular atrial 
fibrillation and its relationship to anticoagulation therapy." Eur J Ultrasound 15(1-2): 
21-7. 
Tong, D. C. and G. W. Albers (1995). "Transcranial Doppler-detected microemboli in 
patients with acute stroke." Stroke 26(9): 1588-92. 
Valton, L., V. Larrue, et al. (1998). "Microembolic signals and risk of early recurrence in 
patients with stroke or transient ischemic attack." Stroke 29(10): 2125-8. 
Wong, K. S. (2005). "Is the measurement of cerebral microembolic signals a good surrogate 
marker for evaluating the efficacy of antiplatelet agents in the prevention of 
stroke?" Eur Neurol 53(3): 132-9. 
Wong, K. S., S. Gao, et al. (2002). "Mechanisms of acute cerebral infarctions in patients with 
middle cerebral artery stenosis: a diffusion-weighted imaging and microemboli 
monitoring study." Ann Neurol 52(1): 74-81. 
Wong, K. S., S. Gao, et al. (2001). "A pilot study of microembolic signals in patients with 
middle cerebral artery stenosis." J Neuroimaging 11(2): 137-40. 
Zuromskis, T., R. Wetterholm, et al. (2008). "Prevalence of micro-emboli in symptomatic 
high grade carotid artery disease: a transcranial Doppler study." Eur J Vasc Endovasc 
Surg 35(5): 534-40. 
www.intechopen.com
Acute Ischemic Stroke
Edited by Prof. Julio Cesar Garcia Rodriguez
ISBN 978-953-307-983-7
Hard cover, 236 pages
Publisher InTech
Published online 18, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Despite significant technological advances in recent years, their impact on our overall health and social, well-
being is not always clear to see. Perhaps, one of the best examples of this can be highlighted by the fact that
mortality rates as a result of cerebrovascular diseases have hardly changed, if at all. This places
cerebrovascular diseases as one of the most prominent causes of both disability and death. In Cuba, for
instance, a total of 22,000 cases of cerebrovascular diseases are reported each year in a country where life
expectancy should increase to 80 years in the near future. In such a situation, to have a book that includes in a
clear and summarized way, a group of topics directly related to the preclinical investigations advances and the
therapeutic procedures for the cerebrovascular disease in its acute phase constitutes a useful tool for the wide
range of the contributors to this affection's problems solution. In this group is included students, professors,
researchers, and health policy makers whose work represents one of the greatest social and human impact
challenges of the XXI century basic and clinical neurosciences.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Titto Idicula and Lars Thomassen (2012). Microemboli Monitoring in Ischemic Stroke, Acute Ischemic Stroke,
Prof. Julio Cesar Garcia Rodriguez (Ed.), ISBN: 978-953-307-983-7, InTech, Available from:
http://www.intechopen.com/books/acute-ischemic-stroke/microemboli-monitoring-in-ischemic-stroke
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
